Cytokinetics, Incorporated (CYTK) is listed on NASDAQ in Pharmaceutical Stocks. It is $72.17, -7.36%, with a $10.0B market cap. RSI is 37.1, near oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 37.1 Near Oversold
Market Cap $10.0B
Volume 3.2M
Fundamentals — 10-Q Q2 2026
Revenue $48.0M
Net Income $-404.8M
EPS $-3.17
Operating Margin -756.1%
Net Margin -843.7%
Debt / Equity -1.4x
P/E Ratio -22.8x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO | Sell | 7,500 | $76.76 | $575,700 | 2026 Aug 10 |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | $79.88 | $1.1M | 2026 Jul 30 |
| Blum Robert I | President & CEO | Sell | 7,500 | $80.87 | $606,525 | 2026 Jul 27 |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $80.59 | $282,065 | 2026 Jul 21 |
| Blum Robert I | President & CEO | Sell | 7,500 | $82.02 | $615,150 | 2026 Jul 13 |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $86.62 | $303,170 | 2026 Jul 7 |
| Blum Robert I | President & CEO | Sell | 7,500 | $84.92 | $636,900 | 2026 Jul 1 |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $85.80 | $1.3M | 2026 Jul 1 |
| Lee Sung | EVP, Chief Financial Officer | Sell | 1,112 | $87.79 | $97,622 | 2026 Jul 1 |
| Lee Sung | EVP, Chief Financial Officer | Sell | 3,134 | $85.00 | $266,390 | 2026 Jun 29 |
| Lee Sung | EVP, Chief Financial Officer | Sell | 38,730 | $82.30 | $3.2M | 2026 Jun 24 |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $79.51 | $278,285 | 2026 Jun 23 |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.46 | $528,450 | 2026 Jun 15 |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $67.98 | $237,930 | 2026 Jun 9 |
| Kaye Edward M. Md | Director | Sell | 2,933 | $76.09 | $223,172 | 2026 Jun 1 |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.1M | 2026 Jun 1 |
| Parshall B Lynne | Director | Sell | 5,000 | $74.08 | $370,400 | 2026 Jun 1 |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.21 | $579,075 | 2026 May 27 |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.69 | $264,915 | 2026 May 19 |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.92 | $584,400 | 2026 May 14 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $76.62 | 35.2 | $15.0B |
| | $64.65 | 51.0 | $12.5B |
| | $18.03 | 47.2 | $6.3B |
| | $366.76 | 62.3 | $542.1B |
| | $113.77 | 55.4 | $12.3B |
Take CYTK further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put CYTK in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Cytokinetics, Incorporated next reports.
Set alerts on CYTK
Get notified when Cytokinetics, Incorporated hits your price targets or technical conditions are met.
Get Started Free